Comparative Pharmacology
Head-to-head clinical analysis: OXYTOCIN 10 USP UNITS IN DEXTROSE 5 versus SYNTOCINON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXYTOCIN 10 USP UNITS IN DEXTROSE 5 versus SYNTOCINON.
OXYTOCIN 10 USP UNITS IN DEXTROSE 5% vs SYNTOCINON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases intracellular calcium in uterine myofibrils, stimulating contractions. Binds to oxytocin receptors in myometrium and mammary glands.
Synthetic oxytocin binds to oxytocin receptors in the myometrium, causing increased intracellular calcium and uterine smooth muscle contraction. Also acts on mammary gland myoepithelium for milk ejection.
IV infusion: 0.5-2 mU/min, increased by 1-2 mU/min every 30-60 min until desired uterine activity, then reduce; max 20 mU/min.
10 units (1 mL) intravenously as a single dose after delivery; continuous infusion: 20 units in 1 L of normal saline or lactated Ringer's solution at 2-10 mU/min (0.1-0.5 mL/min) titrated to uterine response.
None Documented
None Documented
Terminal half-life: 1-6 minutes (IV); clinical effect ceases rapidly after infusion stops due to rapid clearance.
Terminal elimination half-life: 1–6 minutes (intravenous); 1–9 minutes (intramuscular). Clinically, effects dissipate rapidly after infusion cessation.
Renal: >99% as unchanged drug; <1% hepatic metabolism and biliary excretion.
Renal: >99% as intact oxytocin; biliary/fecal: negligible (<1%).
Category C
Category C
Oxytocic
Oxytocic